| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA1201622 |
| P8608 | Fatcat ID | release_wcs4ndnnkvcn5oxyhna7xhqkey |
| P3181 | OpenCitations bibliographic resource ID | 433685 |
| P932 | PMC publication ID | 3951300 |
| P698 | PubMed publication ID | 22853014 |
| P50 | author | Gabriel N Hortobagyi | Q88225186 |
| P2093 | author name string | Daniel F Hayes | |
| Kathy S Albain | |||
| Shaker R Dakhil | |||
| Julie R Gralow | |||
| William E Barlow | |||
| Robert B Livingston | |||
| Rita S Mehta | |||
| Danika L Lew | |||
| Nagendra R Tirumali | |||
| Ted A Vandenberg | |||
| P2860 | cites work | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| Toxicity and response criteria of the Eastern Cooperative Oncology Group | Q29619399 | ||
| Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis | Q33258094 | ||
| Survival differences among women with de novo stage IV and relapsed breast cancer | Q34231099 | ||
| Prednisolone improves the response to primary endocrine treatment for advanced breast cancer | Q36466768 | ||
| Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group | Q37119390 | ||
| Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer | Q40158741 | ||
| Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model | Q40408882 | ||
| Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. | Q42882393 | ||
| Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. | Q43286764 | ||
| Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. | Q43739422 | ||
| Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma | Q43824354 | ||
| Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial | Q44045676 | ||
| Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial | Q44102213 | ||
| Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment | Q44102217 | ||
| Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis | Q44147038 | ||
| Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group | Q44459245 | ||
| Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial | Q44875574 | ||
| Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial | Q46409123 | ||
| Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model | Q46616157 | ||
| A potent specific pure antiestrogen with clinical potential | Q46965638 | ||
| Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. | Q54172521 | ||
| Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer | Q68878798 | ||
| Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer | Q71658545 | ||
| Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study | Q73190388 | ||
| Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group | Q73190394 | ||
| FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer | Q83523415 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metastatic breast cancer | Q12859063 |
| anastrozole | Q419143 | ||
| P304 | page(s) | 435-444 | |
| P577 | publication date | 2012-08-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Combination anastrozole and fulvestrant in metastatic breast cancer | |
| P478 | volume | 367 |
| Q53738984 | 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). |
| Q33900807 | A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer |
| Q53733893 | A Review of Fulvestrant in Breast Cancer. |
| Q43645692 | A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer |
| Q39297345 | A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure |
| Q36903310 | A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer. |
| Q26768665 | ABC3 Consensus Commented from the Perspective of the German Guidelines |
| Q30315301 | ABC3 Consensus: Assessment by a German Group of Experts |
| Q30317569 | AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013 |
| Q28069856 | Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers |
| Q38190106 | Advances in mechanisms of resistance to aromatase inhibitors |
| Q38206546 | Advances in the approach to novel drug clinical development for breast cancer |
| Q39034840 | Advances in the treatment of advanced oestrogen-receptor-positive breast cancer |
| Q26777085 | An Investigation of the Shortcomings of the CONSORT 2010 Statement for the Reporting of Group Sequential Randomised Controlled Trials: A Methodological Systematic Review |
| Q50040088 | An update on first line therapies for metastatic breast cancer |
| Q88188525 | Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials |
| Q94466988 | Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings |
| Q36933778 | Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies. |
| Q38148495 | Breast cancer management in the elderly |
| Q37218214 | Breast cancer metastasis: issues for the personalization of its prevention and treatment |
| Q84937874 | Breast cancer: Anastrozole and fulvestrant--combination to unlock efficacy |
| Q38502890 | Challenges in the management of advanced, ER-positive, HER2-negative breast cancer |
| Q42287317 | Changing T-cell enigma: cancer killing or cancer control? |
| Q38852355 | Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer |
| Q38352305 | Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer |
| Q28081168 | Clinical utilities of aromatase inhibitors in breast cancer |
| Q57107345 | Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence |
| Q64902368 | Combination Therapies in Advanced, Hormone Receptor-Positive Breast Cancer. |
| Q45172965 | Combination endocrine treatments unproven in breast cancer |
| Q33593388 | Combinatorial therapy discovery using mixed integer linear programming |
| Q61809308 | Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib |
| Q37570653 | Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer |
| Q57108041 | Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer |
| Q38785362 | Current challenges of metastatic breast cancer. |
| Q26795751 | Current medical treatment of estrogen receptor-positive breast cancer |
| Q38044021 | Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer |
| Q94347870 | Cyclin‐dependent kinase (CDK) inhibitors for hormone receptor‐positive advanced breast cancer |
| Q33993400 | Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer |
| Q92482005 | ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future |
| Q55361350 | Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis. |
| Q47657661 | Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review |
| Q37045421 | Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. |
| Q33440543 | Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. |
| Q37402732 | Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer |
| Q44871921 | Embryonic transcription factor SOX9 drives breast cancer endocrine resistance |
| Q33617949 | Emerging therapies for breast cancer |
| Q59072640 | Endocrine Resistance in Breast Cancer |
| Q57108908 | Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature |
| Q39185424 | Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer |
| Q91692711 | Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials |
| Q28081872 | Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers |
| Q38120825 | Endocrine therapy: is the first generation of targeted drugs the last? |
| Q39172983 | Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer |
| Q28084585 | Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways |
| Q41625331 | Estrogen and soy isoflavonoids decrease sensitivity of medulloblastoma and central nervous system primitive neuroectodermal tumor cells to chemotherapeutic cytotoxicity |
| Q89495426 | Evaluation of a charity-led secondary breast cancer support day: a model of survivorship care |
| Q53084014 | Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. |
| Q37501868 | Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis |
| Q34485539 | Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients |
| Q37532641 | Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial |
| Q36534686 | Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study |
| Q36924682 | Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. |
| Q30239835 | Fulvestrant for hormone-sensitive metastatic breast cancer. |
| Q33887675 | Fulvestrant in advanced breast cancer: evidence to date and place in therapy |
| Q64898436 | Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review. |
| Q44699072 | Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, mult |
| Q39190569 | Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials |
| Q33880170 | Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs |
| Q99636410 | Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis |
| Q38784116 | Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape |
| Q38784119 | Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape. |
| Q55423791 | Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines. |
| Q38134633 | IAPs on the move: role of inhibitors of apoptosis proteins in cell migration |
| Q39802570 | Information time scales for interim analyses of randomized clinical trials |
| Q36804566 | Interpreting cancer biology: refining our therapeutic algorithm in breast cancer |
| Q54957190 | Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer? |
| Q35000639 | Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells |
| Q38123680 | Luminal breast cancer: from biology to treatment |
| Q57177638 | Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers |
| Q54349937 | Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway. |
| Q56624496 | Metastasiertes Mammakarzinom |
| Q45072397 | Metastatic breast cancer: Endocrine therapy landscape reshaped |
| Q38901163 | Metastatic breast cancer: The Odyssey of personalization |
| Q88890332 | Metastatic breast cancer: focus on endocrine sensitivity |
| Q34253243 | Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors |
| Q90622833 | Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations |
| Q38104670 | Molecular-targeted agents combination therapy for cancer: developments and potentials |
| Q38640774 | Mycologic Endocrinology |
| Q86732550 | Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel |
| Q52942118 | New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies. |
| Q48240854 | New agents for the management of resistant metastatic breast cancer. |
| Q36547566 | New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus |
| Q26797396 | New directions for drug-resistant breast cancer: the CDK4/6 inhibitors |
| Q45910687 | New institute to investigate costs of cancer treatments. |
| Q38071653 | Novel 1H-1,2,3-, 2H-1,2,3-, 1H-1,2,4- and 4H-1,2,4-triazole derivatives: a patent review (2008 - 2011). |
| Q26777683 | Optimal management of hormone receptor positive metastatic breast cancer in 2016 |
| Q64112469 | Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer |
| Q49632496 | Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review |
| Q38068586 | Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition |
| Q55342026 | Overcoming endocrine resistance in hormone receptor-positive breast cancer. |
| Q34657786 | Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. |
| Q35958082 | Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer |
| Q28074156 | Palbociclib: A New Option for Front-Line Treatment of Metastatic, Hormone Receptor-Positive, HER2-Negative Breast Cancer |
| Q38577715 | Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer |
| Q35945939 | Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer |
| Q43777548 | Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy. |
| Q64882842 | Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience. |
| Q37234829 | Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance) |
| Q55353691 | Recent Advances in the Treatment of Breast Cancer. |
| Q89690242 | Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer |
| Q28076777 | Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant |
| Q38374560 | Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer |
| Q38933237 | Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients |
| Q46011982 | SEOM clinical guidelines for the management of metastatic breast cancer 2013. |
| Q49268662 | Steroidal Pyrimidines and Dihydrotriazines as Novel Classes of Anticancer Agents against Hormone-Dependent Breast Cancer Cells. |
| Q91840268 | Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer |
| Q37449530 | Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors |
| Q28080469 | Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines |
| Q38850077 | Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo |
| Q51058385 | Targeted treatments for breast cancer: a step forward. |
| Q36347511 | Targeting Transcription Factors in Cancer |
| Q64119664 | Targeting stem cells in the realm of drug-resistant breast cancer |
| Q38375972 | The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population |
| Q36119749 | The Globalization of Cooperative Groups |
| Q58710786 | The efficacy and safety of targeted therapy plus fulvestrant in postmenopausal women with hormone-receptor positive advanced breast cancer: A meta-analysis of randomized-control trials |
| Q36903188 | The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker |
| Q91372202 | The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013 |
| Q38587521 | The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer |
| Q35827822 | The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer |
| Q38261875 | Transcriptional regulation of human UDP-glucuronosyltransferase genes. |
| Q26785496 | Treating Elderly Patients With Hormone Receptor-Positive Advanced Breast Cancer |
| Q35687540 | Treatment Considerations for the Management of Patients With Hormone Receptor-Positive Metastatic Breast Cancer |
| Q92244163 | Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer |
| Q47809559 | Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer. |
| Q39373643 | Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review |
| Q38100711 | Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer |
| Q36917641 | Willingness of Patients with Breast Cancer in the Adjuvant and Metastatic Setting to Use Electronic Surveys (ePRO) Depends on Sociodemographic Factors, Health-related Quality of Life, Disease Status and Computer Skills |
Search more.